CNSY Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2016βFY2025
Cerenome, Inc. had $5.2M of revenue in fiscal 2025, down 10.5% on the year before.
Last close Β· Oct 23, 2026
$1.64
6.3%Hi! I read Cerenome, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β10.5%
No. Sales fell 10.5% last year.
Does it make a profit?
β429.4%
No. It lost money last year.
Does profit turn into cash?
β399.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
0.1x
One share costs 0.1 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Cerenome, Inc. had $5.2M of revenue in fiscal 2025, down 10.5% on the year before. Its operating margin was β293.5%, down 41.1Β pts: of every 100 in sales, about β293 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Cerenome, Inc. lost $22.4M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$20.8M in fiscal 2025, β399.8% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders bought $0.0M of shares on the open market and sold none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
1 insider
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 4, 2025 | Andrew John Hugh MacIntyre SimsChief Financial Officer | Bought | 20,000 | $0.51 | $0.0M | Form 4 |
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Cerenome, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $18.4M | $18.1M | $8.6M | $3.6M | $8.6M |
| Debt incl. finance leases | $6.6M | $5.4M | $4.0M | β | β |
| Debt / equity | 0.6x | 0.8x | β | β | β |
| Interest coverage | β13.4x | β27.7x | β33.7x | β82.1x | β27.9x |
| Current ratio | 3.4x | 1.8x | 0.9x | 0.3x | 1.2x |
| Quick ratio | 3.4x | 1.8x | 0.9x | 0.3x | 1.2x |
| Total assets | $22.0M | $23.9M | $11.4M | $6.6M | $16.3M |
| Total liabilities | $11.1M | $17.4M | $12.7M | $15.6M | $12.3M |
| Shareholders' equity | $10.8M | $6.4M | β$1.3M | β$8.9M | $4.0M |
| Net debt (β = net cash) | β$11.8M | β$12.7M | β$4.6M | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Cerenome, Inc. passes 3 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 9 | 5 / 9 | 4 / 7 | 0 / 7 | 4 / 7 | 3 / 7 | 1 / 7 | 2 / 7 | 3 / 7 |
| Accruals ratio | β7.3% | β13.8% | β2.4% | β21.1% | 1.1% | β18.3% | β31.9% | β2.6% | β26.9% | β14.0% |
| Altman Z'' | β37.86 | β45.83 | β60.63 | β59.18 | β121.37 | β64.94 | β66.24 | β146.04 | β268.21 | β107.82 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $4.7M | $2.7M | $3.7M | β | β | β | β | $4.9M | $5.8M | $5.2M |
| Gross profit | $1.9M | $0.1M | $2.5M | β | β | β | β | β | β | β |
| Research and development | $16.2M | $11.7M | $5.5M | $5.4M | $2.7M | $5.3M | $9.7M | $9.7M | $10.6M | $8.4M |
| Operating income | β$19.7M | β$20.7M | β$8.8M | β$3.7M | β$9.6M | β$12.5M | β$19.7M | β$13.3M | β$14.7M | β$15.3M |
| Interest expense | $2.6M | $2.0M | $1.9M | $1.9M | $1.1M | $0.9M | $0.7M | $0.4M | $0.2M | $0.5M |
| Pretax income | β$20.4M | β$21.9M | β$8.3M | β$3.4M | β$8.2M | β | β | β | β$13.0M | β$22.4M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | β$22.0M | β$22.7M | β$12.6M | β$10.9M | β$8.2M | β$13.4M | β$20.3M | β$13.3M | β$13.0M | β$22.4M |
| Net income to common | β$22.0M | β$26.7M | β$15.1M | β$11.4M | β$8.2M | β | β | β | β | β |
| Diluted EPS | β$1.28 | β$8.23 | β$86.98 | β$8.27 | β$1.86 | β$1.11 | β$11.58 | β$4.24 | β$2.34 | β$0.29 |
| Diluted shares | 0.02B | 0.00B | 0.00B | 0.00B | 0.00B | 0.01B | 0.00B | 0.00B | 0.01B | 0.08B |
| Cash flow | ||||||||||
| Cash from operations | β$19.5M | β$18.1M | β$12.0M | β$5.9M | β$8.4M | β$10.3M | β$13.0M | β$12.9M | β$10.6M | β$20.8M |
| Capital expenditure | $0.1M | $0.3M | $0.1M | $0.1M | β | β | β | $0.2M | $0.1M | $0.1M |
| Free cash flow | β$19.6M | β$18.4M | β$12.1M | β$6.0M | β | β | β | β$13.0M | β$10.7M | β$20.8M |
| Depreciation and amortization | $1.2M | $2.2M | $2.0M | $0.9M | $0.4M | $0.4M | $0.6M | $0.6M | $0.9M | $0.4M |
| Stock-based compensation | $1.1M | $0.8M | $0.4M | $0.1M | $0.2M | $0.6M | $0.6M | $0.6M | $0.6M | $1.5M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $12.6M | $9.6M | $5.3M | $17.6M | $8.3M | $18.4M | $18.1M | $8.6M | $3.6M | $8.6M |
| Total debt | $17.6M | $13.6M | $14.2M | $11.1M | $6.3M | $6.6M | $5.4M | $4.0M | β | β |
| Finance lease liabilities | β | β | β | $0.1M | $0.0M | β | β | β | β | β |
| Current assets | $18.7M | $14.9M | $9.6M | $19.8M | $9.2M | $19.7M | $21.8M | $9.8M | $5.3M | $15.2M |
| Current liabilities | $12.5M | $18.4M | $17.6M | $14.5M | $8.5M | $5.9M | $11.9M | $10.7M | $15.6M | $12.3M |
| Inventory | $3.7M | $3.2M | $0.1M | $0.1M | β | β | β | β | β | β |
| Property and equipment, net | $1.2M | $3.1M | $2.3M | $2.2M | $1.8M | $1.5M | $1.3M | $0.9M | $0.4M | $0.3M |
| Goodwill | $3.9M | $3.9M | $0.4M | $0.4M | $0.4M | $0.4M | $0.4M | $0.4M | $0.4M | $0.4M |
| Intangible assets | $8.4M | $7.2M | $6.0M | β | β | β | β | $0.0M | $0.5M | $0.3M |
| Total assets | $34.6M | $31.6M | $24.0M | $23.2M | $12.1M | $22.0M | $23.9M | $11.4M | $6.6M | $16.3M |
| Total liabilities | $23.6M | $18.6M | $18.8M | $22.1M | $9.1M | $11.1M | $17.4M | $12.7M | $15.6M | $12.3M |
| Preferred stock | $0.0M | $0.0M | β | β | β | β | β | β | β | β |
| Shareholders' equity | $11.0M | $13.0M | $5.2M | $1.2M | $3.0M | $10.8M | $6.4M | β$1.3M | β$8.9M | $4.0M |
| Margins | ||||||||||
| Gross margin | 41.7% | 5.4% | 68.7% | β | β | β | β | β | β | β |
| Operating margin | β423.2% | β769.2% | β238.7% | β | β | β | β | β271.1% | β252.3% | β293.5% |
| EBITDA margin | β397.9% | β689.2% | β184.1% | β | β | β | β | β258.4% | β237.3% | β284.9% |
| Net margin | β473.5% | β843.7% | β344.2% | β | β | β | β | β271.0% | β222.8% | β429.4% |
| FCF margin | β421.0% | β685.1% | β329.8% | β | β | β | β | β264.8% | β183.7% | β399.8% |
| Returns | ||||||||||
| Return on capital | β97.2% | β95.7% | β48.9% | β | β742.3% | β | β | β | β | β |
| Return on capital employed | β89.1% | β156.7% | β136.2% | β41.8% | β268.8% | β77.5% | β164.1% | β2,015.3% | 164.8% | β381.4% |
| Return on equity | β200.7% | β189.2% | β138.6% | β341.0% | β393.3% | β193.3% | β234.7% | β522.5% | β | β |
| Return on assets | β63.7% | β68.5% | β45.4% | β46.1% | β46.6% | β78.6% | β88.4% | β75.5% | β144.0% | β195.0% |
| Return on tangible equity | β | β1,425.1% | β | β1,451.9% | β309.9% | β128.0% | β333.9% | β | β | β680.2% |
| Growth | ||||||||||
| Revenue growth | β | β42.2% | 36.5% | β | β | β | β | β | 18.5% | β10.5% |
| Share count change | β | β81.3% | β94.6% | 695.9% | 219.9% | 173.0% | β85.5% | 79.4% | 145.2% | 910.3% |
| Financial health | ||||||||||
| Debt / equity | 1.6x | 1.0x | 2.7x | 9.5x | 2.1x | 0.6x | 0.8x | β | β | β |
| Interest coverage | β7.6x | β10.1x | β4.6x | β2.0x | β8.7x | β13.4x | β27.7x | β33.7x | β82.1x | β27.9x |
| Current ratio | 1.5x | 0.8x | 0.5x | 1.4x | 1.1x | 3.4x | 1.8x | 0.9x | 0.3x | 1.2x |
| Quick ratio | 1.2x | 0.6x | 0.5x | 1.4x | 1.1x | 3.4x | 1.8x | 0.9x | 0.3x | 1.2x |
| Capital allocation | ||||||||||
| Capex / revenue | 1.4% | 11.0% | 3.6% | β | β | β | β | 3.3% | 2.5% | 1.3% |
| Stock comp / revenue | 23.2% | 28.0% | 9.7% | β | β | β | β | 11.6% | 9.4% | 29.5% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 5.0 | 4.0 | 0.0 | 4.0 | 3.0 | 1.0 | 2.0 | 3.0 |
| Altman Z'' | β37.9 | β45.8 | β60.6 | β59.2 | β121.4 | β64.9 | β66.2 | β146.0 | β268.2 | β107.8 |
| Accruals ratio | β7.3% | β13.8% | β2.4% | β21.1% | 1.1% | β18.3% | β31.9% | β2.6% | β26.9% | β14.0% |
Source: SEC EDGAR XBRL filings (CIK 0001095981). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.